Zafirlukast
This leukotriene receptor antagonist is taken as a daily oral tablet to prevent asthma symptoms and reduce the need for rescue inhalers. It works by blocking leukotrienes, inflammatory chemicals that cause airway narrowing, mucus production, and swelling in asthma. It is not for immediate relief of an asthma attack and should be continued even when symptoms are absent.
Peso Molecular
575,7000 g/mol
LogP
5,50
TPSA
124,00 Ų
Regra dos 5 de Lipinski
Reprovado
Áreas Terapêuticas
Mecanismo de Ação
Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.
Estrutura 2D
Cite this structure
Embed this structure
SMILES
COc1cc(C(=O)NS(=O)(=O)c2ccccc2C)ccc1Cc1cn(C)c2ccc(NC(=O)OC3CCCC3)cc12
InChI
InChI=1S/C31H33N3O6S/c1-20-8-4-7-11-29(20)41(37,38)33-30(35)22-13-12-21(28(17-22)39-3)16-23-19-34(2)27-15-14-24(18-26(23)27)32-31(36)40-25-9-5-6-10-25/h4,7-8,11-15,17-19,25H,5-6,9-10,16H2,1-3H3,(H,32,36)(H,33,35)
Molecular Formula
C31H33N3O6S
HBD / HBA
2 / 6
Ligações Rotacionáveis
9
Átomos Pesados
41
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Perguntas frequentes
This leukotriene receptor antagonist is taken as a daily oral tablet to prevent asthma symptoms and reduce the need for rescue inhalers. It works by blocking leukotrienes, inflammatory chemicals that cause airway narrowing, mucus production, and swelling in asthma. It is not for immediate relief of an asthma attack and should be continued even when symptoms are absent.
Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.
Yes, Zafirlukast is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL603. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 5717. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="zafirlukast"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/zafirlukast/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/zafirlukast/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/zafirlukast/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="zafirlukast"></drugfyi-drug>